Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
:AARD
AARD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.88 - $19.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.46K
Market Cap
$244.31M
Enterprise ValueN/A
Total Cash (Recent Filing)$141.82M
Total Debt (Recent Filing)$645.00K
Price to Earnings (P/E)―
Beta1.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,696,894
10 Day Avg. Volume49,091
30 Day Avg. Volume42,456
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.50Price Target Upside153.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PositionAARD ended with ~$74M in cash/equivalents, which in conjunction with proceeds from its February IPO, is guided to support operations into 2027.
Product DevelopmentThe HERO study is well designed to optimize the potential for success in addressing the challenging indication of PWS.
Regulatory EnvironmentThe recent approval of Soleno's Vykat XR in PWS highlights a supportive FDA, which should bode well for ARD-101.
Bears Say
CompetitionAardvark will face competition from a newly approved drug that has already been validated by the FDA, potentially impacting its market share.
Market DynamicsThe pricing and competitive landscape dynamics appear favorable for Aardvark, even if the target patient population is small.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $244.31M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Mar 31, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.673 by -$0.037.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,696,894 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.673. Following the earnings report the stock price went up 4.005%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
Aardvark Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (153.11% Upside)
$28.50 (153.11% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
635.64%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$28.50
▲(153.11% Upside)
Technical Analysis
OptimizeRx
―
RAPT Therapeutics
―
Orchestra BioMed Holdings
―
4D Molecular Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
42.27% Insiders
0.76% Mutual Funds
31.23% Other Institutional Investors
24.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---